Drug intelligence / Profile preview

TJC0667

Development stage: Preclinical
Lead developer: TaiwanJ Pharmaceuticals
Modality: Small Molecules

Overview

TJC0667 is a small-molecule antiviral candidate being developed by TaiwanJ Pharmaceuticals for the treatment of COVID-19. It acts as an inhibitor of the SARS-CoV-2 protease (specifically the 3C-like protease or Mpro), which is an essential enzyme for the cleavage of viral polyproteins into functional units required for viral replication. By blocking this proteolytic process, TJC0667 prevents the assembly and maturation of new virions. As of early 2024, the drug is in the preclinical stage, with development efforts focused on liver optimization to improve its metabolic stability and safety profile.

Targets

Mpro (3C-like proteinase of SARS-CoV-2)

Beyond the preview

Go deeper on TJC0667.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TJC0667.

Explore the full profile